Most Read Articles
Stephen Padilla, 4 days ago
Diabetic patients in a decompensated state and who develop type 2 myocardial infarction (MI) have an increased risk for mortality and major adverse cardiac events (MACE), according to a new study. In addition, these patients are potentially at risk for undiagnosed coronary artery disease.
6 days ago
Chocolate consumption is not associated with risk of coronary heart disease (CHD), stroke or both combined in postmenopausal women free of pre-existing major chronic disease, a study suggests.
Pearl Toh, 13 Jul 2018
More intensive lowering of LDL-C levels was associated with a progressively greater survival benefit than less intensive approach, when the baseline LDL-C levels were ≥100 mg/dL, reveals a meta-analysis of 34 randomized trials.
6 days ago
Switching from thiazide diuretic to ipragliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, leads to improvements in metabolic parameters and body mass composition without affecting blood pressure in type 2 diabetes (T2D) patients, a recent study has found.

Subcutaneous secukinumab prevents radiographic progression in psoriatic arthritis

10 Apr 2018

Treatment with subcutaneous secukinumab leads to significant inhibition of radiographic progression and improvement of clinical signs and symptoms in patients with psoriatic arthritis (PsA), according to the results of the FUTURE 5 study.

The phase III study randomly assigned 996 adult patients (mean age 48.8 years; 49.8 percent female; mean time since PsA diagnosis, 6.6 years) to the following treatment arms: secukinumab 300 mg with loading dose (LD; n=222), secukinumab 150 mg with LD (n=220), secukinumab 150 mg without LD (n=222) or placebo (n=332). Treatment was administered at baseline, weeks 1, 2 and 3, and then every 4 weeks from week 4.

At week 16, the primary endpoint of the proportion of patients achieving an American College of Rheumatology 20 (ACR20) response was significantly greater in all secukinumab arms than in the placebo arm (62.6 percent in the 300-mg group, 55.5 percent in the 150 mg with LD group and 59.5 percent in the 150 mg without LD group vs 27.4 percent; p<0.0001 for all).

At week 24, radiographic progression, as measured by van der Heijde-modified total Sharp score, was significantly inhibited in all secukinumab arms vs placebo arm (p<0.01 for 300 mg with LD and 150 mg without LD; p<0.05 for 150 mg with LD).

Adverse event rates at week 24 were comparable across treatment arms: 63.1 percent for 300 mg with LD, 62.7 percent for 150 mg with LD, 61.1 percent for 150 mg without LD, and 62.0 percent for placebo. There were no reports of deaths or new safety signals.

FUTURE 5 demonstrates the efficacy of subcutaneous secukinumab 300 mg and 150 mg, as well as the benefit of an LD regimen (regardless of the dose) especially when aiming for higher levels of response and faster outcomes in joint and skin endpoints, in the treatment of PsA, researchers said.

Moreover, the present data confirm and extend the results of previous studies demonstrating the therapeutic potential of secukinumab in achieving comprehensive treatment goals in PsA, they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 4 days ago
Diabetic patients in a decompensated state and who develop type 2 myocardial infarction (MI) have an increased risk for mortality and major adverse cardiac events (MACE), according to a new study. In addition, these patients are potentially at risk for undiagnosed coronary artery disease.
6 days ago
Chocolate consumption is not associated with risk of coronary heart disease (CHD), stroke or both combined in postmenopausal women free of pre-existing major chronic disease, a study suggests.
Pearl Toh, 13 Jul 2018
More intensive lowering of LDL-C levels was associated with a progressively greater survival benefit than less intensive approach, when the baseline LDL-C levels were ≥100 mg/dL, reveals a meta-analysis of 34 randomized trials.
6 days ago
Switching from thiazide diuretic to ipragliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, leads to improvements in metabolic parameters and body mass composition without affecting blood pressure in type 2 diabetes (T2D) patients, a recent study has found.